Broncho-munal P hard capsules 3.5 mg 30 pcs.

active ingredients: 1 capsule contains 3.5 mg of lyophilized lysate of bacteria Haemophilus influenzae, Streptococcus (Diplococcus) pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Moraxella (Branhamella/Neisseria) catarrhalis;

excipients: propyl gallate, sodium glutamate, mannitol (E 421), magnesium stearate, pregelatinized starch;

shell: indigotine (E 132), titanium dioxide (E 171), gelatin.

Use for the prevention of recurrent respiratory tract infections.

Hypersensitivity to the active substance or any excipient included in the medicinal product.

Children aged 6 months to 12 years.

Cycle of preventive treatment of recurrent respiratory tract infections:

1 capsule per day on an empty stomach for 10 consecutive days per month, for 3 consecutive months.

The interval between courses should be 20 days.

Treatment can be initiated during the acute phase of respiratory tract infections in combination with other treatments.

The capsules can be opened. If the child has difficulty swallowing the capsule, its contents can be mixed in a suitable drink (water, fruit juice, milk).

The drug should be taken in the morning on an empty stomach.

If you forget to give your child medicine, you should give it the next morning.

No clear clinical symptoms of drug overdose have been observed. No cases of overdose have been reported. In case of overdose, consult a doctor.

The reported adverse reactions are classified below according to MedDRA system organ class and frequency: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), including isolated reports, frequency unknown (cannot be estimated from the available data).

Immune system disorders: uncommon – hypersensitivity reactions (erythematous rash, generalized skin rash, erythema, edema, eyelid edema, facial edema, peripheral edema, swelling, facial swelling, pruritus, generalized pruritus, dyspnea).

From the nervous system: frequent – headache.

Respiratory, thoracic and mediastinal disorders: frequent – cough.

Gastrointestinal: frequent – diarrhea, abdominal pain; infrequent – nausea, vomiting.

Skin and subcutaneous tissue disorders: common: rash; uncommon: urticaria; frequency unknown: angioedema.

General disorders: infrequent – increased fatigue; rare – fever.

In case of persistent gastrointestinal or respiratory disorders, treatment should be discontinued. In case of skin reactions, treatment should also be interrupted, as these manifestations may be allergic in nature.

Use during pregnancy or breastfeeding

The medicine is not used during the first three months of pregnancy.

Patients who intend to become pregnant or who have become pregnant should inform their doctor.

Safety during pregnancy has not been established, therefore it is advisable to avoid using the drug during pregnancy.

No studies have been conducted in breastfeeding women. Therefore, caution should be exercised during breastfeeding.

Children

The use of the drug in children under 6 months of age is not recommended due to the immaturity of their immune system. Children over 12 years of age should use Broncho-munal®, 7 mg capsules.

Ability to influence reaction speed when driving vehicles or other mechanisms

Does not affect the ability to drive a car or use mechanisms.

The interaction of the drug with other medications is currently unknown.

Store at a temperature not exceeding 25 °C in the original packaging in order to protect from moisture.

Keep out of reach of children.

Shelf life – 5 years.